Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call

Quest Diagnostics (NYSE: DGX ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Quest Diagnostics reported a 10.2% year-over-year increase in consolidated revenues for Q2 2026, reaching $3.04 billion, with strong growth in physician, hospital, and consumer channels.

The company raised its full-year 2026 guidance, expecting revenues between $11.95 billion and $12.05 billion and adjusted EPS between $11.05 and $11.25, reflecting robust demand and strategic execution.

Quest Diagnostics continues to invest in automation and AI to enhance productivity and quality, contributing to operational excellence and a 3% annual cost savings target.

Collaborations with Corewell Health and Fresenius Medical Care significantly boosted volumes, contributing 9% to Q2 volume growth, while organic volumes increased by 4.1%.

The company is expanding its consumer health and advanced diagnostics offerings, with notable growth in brain health, cardiometabolic tests, and oncology, especially after gaining New York State approval for Haystack MRD.

Management emphasized a strong pipeline of potential collaborations and acquisitions in hospital outreach and highlighted the strategic importance of the RESULTS Act in the context of PAMA reimbursement discussions.

Full Transcript OPERATOR Welcome to the Quest Diagnostics second quarter 2026 conference call.

At the request of the company, this call is being recorded.

The entire contents of the call, including the presentation and the question and answer session that will follow, are the copyrighted property of Quest Diagnostics with